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Neuroblastoma (NB) is the most common extracranial solid tumor in children, accounting
for about 8% of childhood cancers. Despite aggressive treatment, patients suffering from
high-risk NB have very poor 5-year overall survival rate, due to relapsed and/or treatment-
resistant tumors. A further increase in therapeutic dose intensity is not feasible, because it
will lead to prohibitive short-term and long-term toxicities. New approaches with targeted
therapies may improve efficacy and decrease toxicity. The use of drug delivery systems
allows site specific delivery of higher payload of active agents associated with lower
systemic toxicity compared to the use of conventional (“free”) drugs. The possibility of
imparting selectivity to the carriers to the cancer foci through the use of a targeting moiety
(e.g., a peptide or an antibody) further enhances drug efficacy and safety. We have recently
developed two strategies for increasing local concentration of anti-cancer agents, such as
CpG-containing oligonucleotides, small interfering RNAs, and chemotherapeutics in NB. For
doing that, we have used the monoclonal antibody anti-disialoganglioside (GD2), able to
specifically recognize the NB tumor and the peptides containing NGR and CPRECES motifs,
that selectively bind to the aminopeptidase N-expressing endothelial and the aminopepti-
dase A-expressing perivascular tumor cells, respectively. The review will focus on the use
of tumor- and tumor vasculature-targeted nanocarriers to improve tumor targeting, uptake,
and penetration of drugs in preclinical models of human NB.
Keywords: drug delivery, targeting, nanocarriers, tumor vasculature, tumor uptake, tumor penetration,
neuroblastoma
INTRODUCTION
Neuroblastoma (NB) is the most common solid tumor in children
derived from the sympathetic nervous system and the commonest
type of cancer to be diagnosed in the first year of life (1). The effec-
tive treatment of NB, either at advanced stages or at minimal resid-
ual disease, remains one of the major challenges in pediatric oncol-
ogy. While Stage I and II tumors are localized and well differenti-
ated, and can be successfully treated by surgical resection, patients
with stage III and IV tumors present regional and disseminated
disease with poor prognosis and low response to intensive ther-
apeutic intervention and conventional treatments (2). Moreover,
despite some advances, these tumors still have unacceptably low
cure rates, and, even when treatment is successful, the acute and
long-term morbidity of current therapy can be substantial (3, 4).
In vitro preclinical research has identified novel agents with
promising therapeutic potential for the treatment of this malig-
nancy, however their in vivo efficacy is limited by unfavorable
pharmacokinetic properties resulting in either insufficient drug
delivery and penetration into the tumor and/or metastatic sites, or
high systemic and/or organ-specific toxicities.
Currently, anti-tumor compounds share, indeed, two prop-
erties: short half-life and small therapeutic index (the range
of concentration between efficacy and toxicity). However, it
has been demonstrated that the encapsulation of these “drugs”
into nanocarriers drastically ameliorates their kinetic profiles,
increasing tumor targeting and reducing side effects.
NANOCARRIERS FOR DRUG DELIVERY
The medical community has recently sought alternative thera-
pies that improve selective toxicity against cancer cells, while
decreasing side effects. Nano-biotechnology, defined as biomed-
ical applications of nano-sized systems, is a rapidly developing
area within nanotechnology (5). Nanoparticles, such as liposomes,
allow unique interaction with biological systems at the molec-
ular level. They can also facilitate important advances in detec-
tion, diagnosis, and treatment of human cancers and have led to
a new discipline of nano-biotechnology, called nano-oncology.
Nanoparticles are being actively developed for tumor imaging
in vivo, biomolecular profiling of cancer biomarkers, and targeted
drug delivery (6–8).
Growing solid tumors have capillaries with increased perme-
ability as a result of the disease process (e.g., tumor angiogenesis).
Pore diameters in these capillaries can range from 100 to 800 nm.
Drug-containing liposomes that have diameters in the range of
approximately 50–200 nm are small enough to extravasate from
the blood into the tumor interstitial space through these pores
www.frontiersin.org August 2013 | Volume 3 | Article 190 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pastorino et al. Drug-targeting and penetration in neuroblastoma
(9). Normal tissues contain capillaries with tight junctions that
are impermeable to liposomes and other particles of this diame-
ter. This differential accumulation and penetration of liposomal
drugs in tumor tissues relative to normal cells is the basis for
the increased tumor specificity of liposomal drugs relative to free
drugs. In addition, due to impaired and defective lymphatic ves-
sels, tumors lack lymphatic drainage and therefore there is low
clearance of the extravasated liposomes from tumors. Thus, this
liposome-mediated passive targeting can result in increases in drug
concentrations within solid tumors of several-fold relative to those
obtained with free drugs. This phenomenon has been termed the
enhanced permeability and retention effect (EPR) (10–12). This
mechanism of action of the liposomal drugs is thought to be due
to sustained release of drug from the liposomes and diffusion
of the released drug throughout the tumor interstitial fluid, with
subsequent uptake of the released drug by tumor cells.
At present, however, EPR effect has been measured mostly, if
not exclusively, in implanted tumors with limited data on EPR
in metastatic lesions. Moreover, EPR heterogeneity effect in dif-
ferent tumors (with either differences in vessel structures within
a single tumor type, or different pore dimensions in the vascu-
lature and changed pore size with the location for a given type
of tumor) as well as limited experimental data from patients on
the effectiveness of this mechanism, seems to hamper the progress
in developing drugs using this approach (13). Furthermore, EPR
effect has been demonstrated to be insufficiently performatory in
different animal models of human NB used for testing our pre-
clinical nanocarriers-based therapies (14–19), likely because of the
above mentioned tumor heterogeneity.
Consequently, in the attempt of globally increasing the speci-
ficity of interaction of liposomal drugs with target cells and
the penetration of more amount of drug delivered to latter,
recent efforts in the nanocarriers field have been addressed to the
development of Ligand-Targeted Liposomes (LTLs). These lipo-
somes utilize targeting moieties coupled to the liposome surface,
for delivering the drug-liposome package to the desired site of
action (active targeting). Targeting moieties may include anti-
body molecules, or fragments thereof, small molecular weight
naturally occurring or synthetic ligands like peptides, carbo-
hydrates, glycoproteins, or receptor ligands, i.e., essentially any
molecule that selectively recognizes and binds to target antigens
or receptors over-expressed or selectively expressed on cancer
cells (20).
The great advantages of LTLs encapsulating cytotoxic drugs
over free drugs have been unquestionably demonstrated in a num-
ber of experimental models of cancer (15, 20–22). The mechanism
whereby LTLs appears to act is related to the specific binding of
the drug carrying liposomes to the selective receptor expressed on
cell surface of tumor cells and the subsequent internalization of
the liposomal drug package.
Interestingly, localized release of the encapsulated drug at the
targeted cell surface may occur, contributing to the mechanism of
drug penetration and cytotoxicity mainly due as a consequence of
binding to the specific receptor(s) (11, 20). Since most tumors are
heterogeneous with regard to tumor-associated-antigen expres-
sion, another advantage may be the “bystander effect”: specific
binding of LTLs to a tumor cell, with release and diffusion of
the drug into tumor parenchyma may result in cytotoxicity of
bystander tumor cells lacking the specific epitope. It has been
shown that approximately 400-fold more monoclonal antibody
was required to achieve similar results with antibody-drug con-
jugates. Hence, high drug: antibody ratios can be achieved with
LTLs, thus decreasing the need for expensive and potentially
immunogenic antibodies.
TUMOR CELL TARGETING LEADS TO INCREASED UPTAKE OF
ANTI-CANCER AGENTS IN NB
Neuroblastoma tumors express abundant amounts of the disialo-
ganglioside GD2 at the cell surface and this epitope is only min-
imally expressed by normal tissues, such as the cerebellum and
peripheral nerves (23), thus the use of anti-GD2 whole antibod-
ies or their corresponding Fab′ fragments were used as a selective
ligand for targeting liposomal “drug” to human NB cells.
Below are reported our recent results obtained by using “drug”-
loaded, nanocarrier-mediated targeting of the GD2 epitope, via
coupled anti-GD2 whole antibodies, with improved uptake and
penetration of drugs into experimental models of human NB.
LIPOSOMAL FENRETINIDE
Due to the success of 13-cis-retinoic acid in NB high-risk patients
with elevated frequency of relapse from minimal residual disease
(24), an increased scientific interest has been consolidated in devel-
oping retinoids, a known class of molecules able to trigger both
terminal differentiation and apoptosis/necrosis on NB cells (25,
26). In this scenario, newer chemotherapeutic approaches also
count on the addition of more potent retinoids, such as fenre-
tinide (HPR), a synthetic retinoic acid derivative, which has a very
low degree of toxicity relative to others and has shown efficacy
as a highly active and promising therapeutic and chemopreven-
tive agent in different experimental models and clinical trials (27,
28). However, despite good tolerability in humans, therapeutic
efficacy of HPR is limited by its relatively poor bioavailability par-
ticularly from ingested tablets (29). Indeed, the phase II study of
oral capsular HPR has recently underlined how, this formulation
is characterized by intraindividual and interindividual variation
in pharmacokinetic features as HPR is too lipophilic to easily
pass the intestinal membrane (30). This hindrance has prompted
scientists to draw clinical protocols based on more appropriate
HPR formulations with improved biodistribution after both oral
route and intravenous injection and suitable also for pediatric
use. Maurer et al. (31) has proposed a lipid complex to deliver
HPR, called 4-HPR/Lym-X-Sorb (LXS), that was able to improve
the retinoid solubility and oral bioavailability and to significantly
increase plasma and tissue levels in mice (32). On the other hand,
an in vitro study has proposed, as novel carriers for HPR, specific
amphiphilic macromolecules formed by branched polyethylene
glycol covalently linked with alkyl hydrocarbon chains: in this for-
mulation, HPR is entrapped onto hydrophobic inner cores and
the resultant complexes have dimensions suitable for intravenous
administration (33).
In order to improve tumor targeting, drug stability, and drug
pharmacokinetics and bioavailability, we designed a formula-
tion of HPR, encapsulated in sterically stabilized, GD2-targeted
immunoliposomes [GD2-SIL(HPR)]. We demonstrated that HPR
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efficiently induced a dramatic inhibition of metastases, leading to
almost 100% of curability in NB-bearing mice, only when encap-
sulated in GD2-targeted nanocarriers (14). These achievements
totally disappeared when HPR was administered either free (free
HPR) or loaded in non-targeted liposomes [SL(HPR)], confirm-
ing the importance of the tumor targeting as a mandatory tool
for enhancing binding, uptake, and anti-tumor effects against NB
(Figure 1A).
On the other hand, in this NB animal model, anti-GD2
monoclonal antibody (anti-GD2 mAb) also led to a consider-
able anti-tumor effect, indicating that the anti-GD2 “di per se”
was responsible of part of the observed therapeutic effects
(Figure 1B) (14). Thus, in the subsequent therapeutic, liposomes-
based experiments we decided to use nanocarriers decorated with
the non-immunogenic Fab′ fragments of anti-GD2, thus avoiding
antibody-dependent cell cytotoxicity.
Indeed, the coupling of antibody Fab′ fragments instead of
whole immunoglobulin molecules abolishes the mononuclear
phagocyte system uptake of the anti-GD2, which takes place via an
Fc receptor-mediated mechanism (34). Consequently, small LTLs
decorated with Fab′ fragments have significantly longer circula-
tion time than comparable formulations containing whole mAbs
(20). This can result in an enhanced accumulation of the lipo-
somes in solid tumor (35) and in a significant suppression of
tumor growth (36, 37).
Here, we present some results obtained by using Fab′ fragments
of anti-GD2 immunoliposomes to increase uptake and anti-tumor
activity of CpG-containing antisense oligonucleotides (asODNs),
small interfering RNAs (siRNAs), and chemotherapeutics in
animal models of human NB.
LIPOSOMAL ANTISENSE OLIGONUCLEOTIDES
The identification of cancer-associated genes hold promise for
the development of novel therapeutic strategies that selectively
target tumor cells. asODNs can be used to specifically down
modulate tumor associated gene expression (resulting in a direct
anti-cancer effect) and as immune adjuvant by CpG-containing
asODN-driven cytokines production and innate immune stim-
ulation (38). However, since the in vivo applicability of ODNs
is impaired by their high sensitivity to extracellular and cellular
nuclease degradation (39), their encapsulation within liposomes
should increase their stability. C-myb gene expression has been
reported in several solid tumors of different embryonic origin,
including NB, where it is linked to cell proliferation and/or differ-
entiation (40, 41). We performed a new technique to encapsulate
CpG-containing c-myb asODNs within lipid particles. Liposomes
resulting from this technique were called coated cationic lipo-
somes (CCLs) (41), since they were made up of a central core of a
cationic phospholipids bound to myb asODNs and an outer shell
of neutral lipids.
Fab′-GD2-targeted, CpG-containing c-myb asODNs-loaded
CCLs reduced in a specific and time-dependent manner the
expression of c-Myb protein by NB cells (Figure 2A). Importantly,
we also demonstrated that their systemic administration in NB-
bearing mice, induced anti-tumor effects with increased survival
only when encapsulated in nanocarriers targeting the NB surface
antigen, GD2, that internalizes after binding its ligand (Figure 2B)
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FIGURE 1 | Survival of neuroblastoma-bearing mice after treatment
with fenretinide (HPR)-containing nanocarriers. Nude mice were
injected intravenously with 3×106 HTLA-230 cells, and treated 4 h after
with the following HPR formulations for 5 days: (A) Hepes Buffer pH 7.4,
control (CTR); free HPR, 15 mg/kg/total dose; SL(HPR), 15 mg/kg/total dose;
GD2-SL(HPR), 15 mg HPR/kg/total dose (containing 2 mg mAb/kg/total
dose). In a second experiment (B), a group of mice were treated with 2 mg
of GD2 monoclonal antibody/kg/total (anti-GD2 mAb). All the experiments
have been performed with n=10 animals/group.
(17). We further demonstrated that increased animals life span
was due to a dual mechanism of action. Firstly, a direct inhibition
of tumor growth, via tumor cell binding, uptake, and inhibition
of c-myb proto-oncogene expression; secondly, an indirect CpG-
dependent immune stimulation, whose function was lost as the
result of using clodronate-driven macrophage depletion in nude
mice (Figure 2C) and B and NK cells depletion in SCID-bg mice
(Figure 2D) (17).
LIPOSOMAL SMALL INTERFERING RNAs
Despite the considerable potential of RNA interference (RNAi)
for treating cancers (42, 43), several challenges still need to be
overcome for exogenous siRNAs to be widely used as cancer ther-
apeutics. The most significant hurdle is the specific and non-toxic
delivery of siRNAs to the site of action. siRNA applications are so
far limited almost to targets within the liver, where the delivery
systems naturally occur, while delivery of siRNAs to extra-hepatic
targets remain a serious challenge.
In order to solve this limitation, we consequently developed
a new tumor-targeted delivery system for siRNAs, through their
encapsulation into Fab′ fragments GD2-targeted coated CCLs,
and validated their ability to silence the oncogene anaplastic lym-
phoma kinase (ALK) by increasing NB tumor binding and siRNA
penetration-driven anti-tumor effect.
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FIGURE 2 | Inhibition of c-Myb protein expression and increase of
survival of neuroblastoma-bearing mice after treatment with c-myb
antisense oligonucleotides (asODNs)-containing nanocarriers. (A)
GI-LI-N neuroblastoma cells were treated with CpG-containing c-myb
asODNs, either free (free CpG-myb-as) or encapsulated in untargeted
[CCL(CpG-myb-as)] and targeted [Fab′-GD2-CCL(CpG-myb-as)] nanocarriers,
at a concentration of 100µg/ml at the beginning of the experiment and 18
and 36 h later. Two hours after each addition, the cells were washed and
transferred to CpG-myb-as-free fresh complete medium. The cells were
harvested at 48 h (upper panel) or at the indicated time points (lower panels)
and analysis of protein expression (c-Myb and c-Myc as control) was
performed by immunoblotting. (B) Nude mice (n=10 animals/group) were
injected intravenously with 3.5×106 HTLA-230 cells. Treatment with either
as or scrambled (scr), CpG-containing ODNs, administered free and
encapsulated in untargeted (CCL) and targeted (Fab′-GD2-CCL) liposomes
was started at 4 h after cell inoculation. Mice were treated 4 days a week,
for 2 weeks, with 3 day rest between treatments. Each mouse received
50µg ODN. Control mice (CTR) received HEPES-buffered saline. (C,D)
Effects of either macrophages or natural killer (NK) cells depletion on
anti-tumor activity mediated by treatment with liposomal formulations
containing ODNs. Mice [nude, n=8 animals/group (C) and SCID-bg, n=10
animals/group (D)] were inoculated with HTLA-230 cells and then treated as
already mentioned in Figure 1. In some treatment groups of (C), mice were
injected with Clodronate-liposomes to deplete macrophages.
Indeed, over expression of either mutated or wild-type ALK
tyrosine kinase receptor proteins induces constitutive kinase activ-
ity in NB (44), while ALK expression knockdown leads to a
pronounced decreased cell proliferation. Moreover, ALK muta-
tions and amplifications, as well as gene over expression, clearly
correlate with poor outcomes in both advanced and metastatic
NB disease, when compared with localized tumors (44). Based on
these concepts, we tested the therapeutic efficacy of targeting ALK
gene in NB, by developing a selective silencing approach (45).
We showed that, while almost no binding and uptake
was observed by siRNA-containing, untargeted liposomes
[CCL(siRNA)] in NB cells, Fab′-GD2-targeted CCL(siRNA) were
efficiently internalized (Figure 3A). Interestingly, in biologically
relevant NB animal models, we demonstrated that, compared to
free ALK-siRNA, Fab′-GD2-CCL(ALK-siRNA) increased siRNA
stability, and a selective block of NB tumor growth, resulting in
partial tumor regression (Figure 3B), improved silencing of the
specific gene (Figure 3C), and increased life span in NB xenografts
(Figure 3D) (45). This strategy also induced inhibition of
angiogenesis and of metastatic potential in a safe and highly effec-
tive manner (46), confirming the pivotal role of targeted therapies
to enhance tumor “drug” penetration and cytotoxic effects.
LIPOSOMAL DOXORUBICIN
To eradicate tumors with chemotherapy, anti-cancer drugs must
reach lethal concentrations, in theory, in all of the tumor cells.
Failure to achieve high local levels of drugs, e.g., due to lim-
ited drug delivery and/or penetration within tumors is critical
for the effectiveness of solid-tumor chemotherapy (47). Meth-
ods for improving drug delivery and penetration in tumor tissues
are, therefore, of great experimental and clinical interest. On this
direction, one approach to selective eradicate NB tumor cells is
based on the fact that NB is a chemosensitive tumor and cytotoxic
agents, such as doxorubicin (DXR), are considered to be effective
treatment modalities. However, the therapeutic efficacy of DXR,
which is widely used in the treatment of solid tumors, is restricted
by dose-limiting toxicity to bone marrow and heart tissue (48).
The selective toxicity of DXR would be greatly improved if the
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FIGURE 3 | Neuroblastoma-targeted nanoparticles entrapping siRNA
specifically knockdown ALK. (A) Uptake and internalization of
liposome-encapsulated FAM-labeled scrambled-siRNA (scr-siRNA-FAM) into
GD2-expressing neuroblastoma cells (SH-SY5Y). Cells were incubated at 37°C
for 1 h, with either untargeted [CCL(scr-siRNA-FAM)] or Fab′ fragments
GD2-targeted coated cationic liposomes [Fab′-GD2-CCL(scr-siRNA-FAM)]. After
washing and cytospin centrifugation, cells were fixed and stained with a
monoclonal antibody specific for the cellular adhesion molecule N-CAM
(a-CD56) to reveal plasma membrane localization. Cell nuclei were stained
with 4′,6-diamidino-2-phenylindole (DAPI). The cellular distribution of
scr-siRNA-FAM (green), CD56 (red), nuclear DAPI staining (blue), and merged
colors resulting from siRNA-liposome binding to the cell surface (orange)
fluorescences was analyzed with a laser scanning spectral confocal
microscope. Bars: 50µm. (B–D) Tumor growth inhibition in vivo by ALK-siRNA
encapsulated in Fab′-GD2-CCL. SCID-bg mice (n=8) were orthotopically
injected with 1.5×106 SH-SY5Y cells in the capsule of the left adrenal gland.
Seven days after the tumor implantation, mice were treated, two-time a week
for 3 weeks with ALK-siRNA, either free or encapsulated in GD2-targeted
nanocarriers [Fab′-GD2-CCL(ALK-siRNA)]. Another group of mice received a
scrambled (scr) siRNA-loaded nanoparticles [Fab′-GD2-CCL (scr-siRNA)] as
control or HEPES-buffered saline (CTR). Tumor expansion over time measured
by calipers (B) and survival times (D) were used for determination of the
treatment efficacy. (C) The day after the last treatment (25 day), tumors from
three mice per group were recovered for western blot analyses and ALK
protein expression. *P <0.05; **P < 0.01; ***P <0.001,
Fab′-GD2-CCL(ALK-siRNA) vs. Fab′-GD2-CCL(scr-siRNA).
concentration of drug in tumors could be increased relative to
that in sensitive normal tissues.
Two strategies, based on tumor and vascular targeting, have
been recently described for increasing the local concentration of
the chemotherapeutic drug DXR in tumors and its therapeutic
index. The first strategy is based on the direct targeting of the
tumor cells by the use of Fab′ fragments of GD2-targeted DXR
liposomal [Fab′-GD2-SIL(DXR)] (15). The second approach that
will be discussed in the next chapter, is based on direct targeting
of the tumor vasculature, using DXR encapsulated into modi-
fied liposomes able to bind and home to tumor blood vessels
(16, 21, 49).
In the first study Fab′-GD2-SIL(DXR) has presented increased
selectivity and efficacy in inhibiting NB cell proliferation com-
pared to free drug and non-targeted DXR formulation. The
in vivo anti-tumor activity of Fab′-GD2-SIL(DXR) was evaluated
in terms of metastasis growth inhibition and increased life span
in a pseudometastatic animal model of human NB. In this study,
100% of mice treated with DXR-loaded Fab′-immunoliposomes
1 day after tumor cells injection,were still alive more than 4 months
after treatment. DXR administered either free or encapsulated in
non-targeted nanocarriers did not show any anti-tumor effect,
again confirming the important role of the specific tumor target-
ing in improving drug uptake and consequent tumor cells killing
(Figure 4A) (15).
The next aim was to verify whether these anti-tumor effects
were maintained in more established tumors or if the thera-
peutic efficacy declined when treatment was delayed. Indeed,
a longer period of time between inoculation of cells and the
administration of treatment would allow the tumor cells to estab-
lish metastases that might escape treatment. The metastatic cells
would become less accessible from the vasculature and the tumor-
targeted liposomes become less effective as their accessibility to
the tumor cells becomes compromised. As expected, a delay in the
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FIGURE 4 | Survival of neuroblastoma-bearing mice after treatment
with doxorubicin (DXR)-containing, GD2-targeted nanocarriers. (A)
Nude mice received injections in the tail vein with 4×106 HTLA-230 cells
and 1 and 3 days post-inoculation mice received 5 mg/kg of DXR. Treatment
groups (n=8/group) consisted of DXR administered either free (free DXR)
or encapsulated in untargeted [SL(DXR)] and targeted [Fab′-GD2-SIL(DXR)]
nanocarriers. (B) Nude mice (8/group), inoculated i.v. with 4×106 HTLA-230
cells, were treated on days 1, 2, 5, or 10 with 8 mg DXR/kg/week×2 as
Fab′-GD2-targeted nanocarriers [Fab′-GD2-SIL(DXR), t1, t2, t5, t10,
respectively). Control mice (CTR) received HEPES-buffered saline. Partially
reproduced from Pastorino et al. (21).
start of treatment substantially reduced the therapeutic efficacy
of Fab′-GD2-SIL(DXR), demonstrating the time dependence of
the anti-tumor activity of the tumor-targeted formulation against
advanced NB animal models (Figure 4B). However, with increas-
ing time, the new lesions begin to recruit blood vessels to support
their growth and the lesions will have increased sensitivity to anti-
vascular therapy with time (21). Thus, our findings suggest the
subsequent use of therapies targeting the vascular network of the
tumor, as discussed below, to treat more mature solid tumors.
INCREASING LOCAL CONCENTRATION OF ANTI-CANCER
AGENTS IN NB BY TUMOR VASCULATURE TARGETING
STRATEGY
The alternative strategy we pursued to increase the delivery and the
uptake of DXR into NB is based on the use of tumor vasculature-
targeted liposomes. The targeting of therapeutics to blood vessels,
using probes that bind to specific molecular addresses in the
vasculature, has indeed became a major research area (50). The
inhibition of tumor growth by attacking the vascular supply of
the tumor offers a primary target for therapeutic intervention.
Indeed, host endothelial cells are believed to play a central role
in tumor growth, progression, and metastasis, acting as the pri-
mary building blocks of the tumor microvasculature (51). Because
of the “angiogenesis dependence” of solid tumors, predicted by
Folkman nearly 40 years ago, selective inhibition or destruction
of the tumor vasculature (using anti-angiogenic or anti-vascular
treatments, respectively) could trigger tumor growth inhibition,
regression, and/or a state of dormancy and thereby offer a novel
approach to cancer treatment.
There are several advantages of targeting chemotherapeutic
agents to proliferating endothelial cells in the tumor vasculature
rather than directly to tumor cells. First, acquired drug resis-
tance, resulting from genetic and epigenetic mechanisms reduces
the effectiveness of available drugs (52). Anti-angiogenic/anti-
vascular therapy has the potential to overcome these problems
or reduce their impact. The tumor vasculature, composed of non-
malignant cells that are genetically more stable than malignant
cells, is therefore unlikely to mutate into drug-resistant vari-
ants. Second, the fact that a large number of cancer cells depend
upon a small number of endothelial cells for their growth and
survival might also amplify the therapeutic effect (53). Third,
anti-angiogenic therapies may also circumvent what may be a
major mechanism of intrinsic drug resistance, namely insuffi-
cient drug penetration into the interior of a tumor mass due to
high interstitial pressure gradients within tumors (54). A strat-
egy that targets both the tumor vasculature and the tumor cells
themselves may be more effective than strategies that target only
tumor vasculature, since this strategy can leave a cuff of unaffected
tumor cells at the tumor periphery that can subsequently re-grow
and kill the animals (55). Fourth, oxygen consumption by neo-
plastic and endothelial cells, along with poor oxygen perfusion,
creates hypoxia within tumors. These pathophysiological charac-
teristics of solid tumors compromise the delivery and effectiveness
of conventional cytotoxic therapies as well as molecularly targeted
therapies (53, 54). Finally, the therapeutic target is independent of
the type of solid tumor; killing of proliferating endothelial cells in
the tumor microenvironment can be effective against a variety of
malignancies.
Phage display technology has been recently used to discover
novel ligands specific to receptors on the surface of tumor epithe-
lial and endothelial cells (56). In vivo panning of phage libraries
in tumor-bearing mice has selected peptides that interact with
proteins expressed on tumor-associated vessels and that home to
neoplastic tissues (57). This technology, for instance, was used to
isolate peptides homing specifically to the tumor blood vessel-
associated addresses, aminopeptidase N (APN) and A (APA) (58,
59). We have firstly demonstrated that liposome-entrapped DXR,
and targeted to APN via an NGR-containing peptide, induced
tumor regression, pronounced destruction of the tumor vessels,
and prolonged survival in NB-bearing mice (16).
Specifically, to determine whether the NGR-targeted lipo-
somes [NGR-SL(DXR)] could deliver DXR to angiogenic tumor-
associated blood vessels, we injected them into the tail vein of mice
bearing established adrenal tumors. In one set of experiments,
liposomes were allowed to circulate from 2 to 24 h, followed by
perfusion and immediate tissue recovery. There was a clear time-
dependent uptake of DXR in the tumor vasculature. At 24 h, the
staining pattern indicated that the DXR had spread outside the
blood vessels and into the tumors (16). This spreading was attrib-
utable to increased permeability of tumor blood vessels to the
intact liposomes (60) and/or uptake of the targeted liposomes
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by angiogenic endothelial cells and subsequent penetration and
transfer to tumor cells. Likely both mechanisms are working at
the same time. In the second set of experiments, tissues were
examined 16 h after the injection of DXR-loaded liposomes, dec-
orated with either the specific NGR [NGR-SL(DXR)] or with the
miss-matched ARA [ARA-SL(DXR)] peptides. Strong DXR stain-
ing in tumor vasculature was seen only in animals treated with
NGR-liposomes (Figure 5A). Tumor-specific DXR uptake was
completely blocked when mice were co-injected with a 50-fold
molar excess of the soluble NGR peptide (16), confirming the
peptide recognizing tumor vasculature-driven cell drug binding
and penetration.
Histopathological analysis of cryosections taken from NGR-
SL(DXR) treated mice revealed pronounced destruction of the
tumor vasculature. Indeed, double staining of tumors with
TUNEL and anti-factor VIII antibody or anti-human NB, demon-
strated endothelial cell apoptosis in the vasculature as well
as increased tumor cell apoptosis (16). Moreover, mice dis-
played rapid tumor regression, inhibition of metastases growth,
and suppression of blood vessel density, while mice treated
with ARA-SL(DXR) formed large well-vascularized tumors
(Figures 5B–D) (16).
Subsequently, we developed a novel liposomal formulation tar-
geting the perivascular tumor cell marker APA, expressed in the
vascular wall of NB primary and metastatic lesions.
The primary goal of this study was to validate the hypoth-
esis that the combined targeting of both the tumor endothelial
cells (recognizing APN) and the pericytes (recognizing APA), sup-
porting the vessels wall within the tumor, has improved tumor
targeting, uptake, drug penetration, and therapeutic effects relative
to each therapy alone.
Neuroblastoma-bearing mice receiving APA-targeted liposo-
mal DXR [CPRECES-SL(DXR)] exhibited an increased life span
in comparison to control mice, but to a lesser extent relative to that
in mice treated with APN-targeted formulation [NGR-SL(DXR)]
(18). However, mice treated with a combination (COMBO) of
APA- and APN-targeted, liposomal DXR had an enhanced accu-
mulation of both the carriers and the drug in the tumor mass
(Figures 6A,B), and a significant increase in life span compared
to each treatment administered separately (18). There was a sig-
nificant increase in the level of apoptosis in the tumors of mice
on the combination therapy, and a pronounced destruction of
the tumor vasculature with nearly total ablation of endothelial
cells and pericytes (Figure 6C). Thus, these results clearly demon-
strated that the combined targeted strategy, through an increased
drug penetration, was more effective for destruction of the tumor
vasculature than either monotherapy. Combination therapy led
to a statistically significant increase in life span in a murine
xenograft model of human NB compared to the formulations
given alone (18).
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FIGURE 5 | Anti-angiogenic and anti-tumor effects of doxorubicin
(DXR)-containing, tumor vascular targeted nanocarriers. (A) Tumor
homing of NGR-targeted liposomal DXR in SCID mice orthotopically
injected in the left adrenal gland with 1.5×106 SH-SY5Y neuroblastoma
cells. DXR-loaded, either NGR-targeted or miss-matched peptide
ARA-targeted nanocarriers, were injected via the tail vein as a single bolus
dose. After 16 h, tumors were collected and DXR (red) visualized by
fluorescence microscopy of fixed, paraffin embedded, tissue sections.
(B–D) Delivery of DXR to tumor vessels inhibits angiogenesis, causing
regression of established NB tumors. SCID mice orthotopically implanted
with SH-SY5Y cells were injected intravenously with 3 mg DXR/kg, 21, 28,
and 35 days post tumor inoculation. Treatment groups (n=8/group)
consisted of DXR administered either free (free DXR) or encapsulated in
untargeted [SL(DXR)] and either NGR-targeted [NGR-SL(DXR)] or
miss-matched peptide ARA-targeted [ARA-SL(DXR)] nanocarriers. Control
mice (CTR) received HEPES-buffered saline. (B) Tumor vessels density
inhibition after NGR-targeted liposomal DXR treatments. Orthotopic
tumors, at day 36 from CTR and from both NGR- and ARA-targeted,
DXR-treated groups, were sectioned and stained with an antibody to factor
VIII to count blood vessels. Each bar represents the mean±SD of five
replicates. (C) Neuroblastoma tumor growth arrest by NGR-targeted
liposomal DXR. Each point represents the mean±SD of six replicates. (D)
Increase in animal life span by NGR-targeted liposomal DXR. Partially
reproduced from Pastorino et al. (16).
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FIGURE 6 | Combined targeting of endothelial and perivascular tumor
cells enhances anti-tumor efficacy of liposomal doxorubicin (DXR) in
neuroblastoma. (A,B) Accumulation of APN- and APA-targeted, DXR-loaded,
nanocarriers in nude mice orthotopically implanted with GI-LI-N
neuroblastoma cells. (A) 3H-labeled, endothelial- (via NGR peptide) and
perivascular- (via CPRECES peptide) targeted, DXR-loaded nanocarriers were
injected intravenously in a single bolus. Treatment groups consisted of
NGR-3H-SL(DXR), CPRECES-3H-SL(DXR), and combination of targeted
liposomes (COMBO). At selected time points post-injection, blood was
measured for 3H in a beta-counter. Points, average of three mice; bars, ±95%
C.I. (B) Tumor accumulation of DXR visualized by fluorescence microscopy of
NB tissue sections. Magnitude, 40×. (C) Effects of the combination therapy
on endothelial, perivascular, and tumor cells in vivo. Immunohistochemistry
was performed on established NB tumors removed from untreated mice
(CTR) or from mice treated with DXR-loaded, NGR-targeted or
CPRECES-targeted nanocarriers, or with a combination of the two liposomal
formulations (COMBO). Tumors were removed on day 36 and tissue sections
were immunostained for CD31 and SMA to detect tumor vasculature (scale
bar, 250µm). TUNEL was performed to detect tumor apoptosis (scale bar,
100µm). Cell nuclei were stained with DAPI. Columns, mean of CD31, SMA,
and TUNEL staining intensities; error bars represent 95% C.I. **P <0.01;
***P <0.001, COMBO vs. single treatments.
CONCLUDING REMARKS
In a tumor mass, neoplastic cells and the vascular endothelium
of angiogenic blood vessels that support tumor growth express
targetable surface markers that are accessible from the circulation.
Thus, targeting therapeutic agents to tumor cells and to tumor
vessels made it possible to deliver the anti-cancer agents to the
tumor site, and to combine blood vessel destruction with the con-
ventional anti-tumor actions of drugs, leading to more efficacious
effects and less systemic toxicity than conventional therapy.
However, despite good results obtained in preclinical experi-
mental models, targeted therapies have also practically met with
some drawbacks, restricting their clinical translation. In particular,
this approach has only a partial success for the treatment of well-
established solid tumors, where tumor vessels are poorly perfused
with blood and are dysfunctional, limiting the delivery of blood-
borne compounds into the tumor masses (61). Tumors have also
an high interstitial pressure deriving from dysfunctional lymphat-
ics, which causes tissue fluid to flow out of the tumor thus reducing
diffusion of drugs from the blood vessels into the tumors (61,
62). Finally, interstitial fibrosis can further retard the diffusion of
targeted compounds through the dense tumor parenchyma (63).
Consequently, to further overcome these drawbacks and to
increase anti-tumor efficacy of the targeted therapies, in the near
future the use of targeting probes with even more enhanced tumor-
penetrating properties and receptors that are likely shared between
tumor vessels and tumor cells should be envisaged.
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